GlobalData on MSN19h
Valneva hits 2024 sales target but plans lower cash burn in 2025Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback